Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacology data can feel like decoding another language, and Ardelyx’s reports are no exception. Each Ardelyx annual report 10-K simplified on Stock Titan lays out pivotal details—cash runway, Phase 3 results for tenapanor, and royalty streams from overseas partners—that investors must grasp before the next catalyst hits. Our platform turns those dense pages into plain-English answers, giving you Ardelyx SEC filings explained simply without hours of scrolling.
Need specific numbers fast? Open any Ardelyx quarterly earnings report 10-Q filing and our AI instantly flags enrollment costs, FDA meeting minutes, and revenue from IBS-C sales. Toggle to Ardelyx insider trading Form 4 transactions or set alerts for Ardelyx Form 4 insider transactions real-time to spot executive stock moves before markets react. Curious about sudden news? The moment management files an Ardelyx 8-K material events explained notice—whether a trial read-out or partnership amendment—you’ll see a concise summary plus contextual ratios that matter.
Researchers, portfolio managers, and retail traders rely on different forms for different insights. The proxy statement section answers questions like “Ardelyx proxy statement executive compensation” by detailing option grants and pay mixes. “Understanding Ardelyx SEC documents with AI” also means seeing drug milestone obligations right beside balance-sheet impacts. From tracking Ardelyx executive stock transactions Form 4 to diving into an Ardelyx earnings report filing analysis, every disclosure updates in real time, complete with expert commentary so you can act on data instead of digging for it.
Ardelyx (ARDX) appointed Sue Hohenleitner as chief financial officer and principal financial officer, effective November 4, 2025. A veteran of Johnson & Johnson, she most recently served as CFO of J&J Innovative Medicine North America.
Her compensation includes a $550,000 base salary, a target bonus of 45% of salary (pro‑rated for 2025), a $180,000 sign‑on bonus, and a $150,000 housing payment. Upon her October 13, 2025 employment start, she received options for 578,104 shares at $5.01 per share and 146,896 RSUs. Options vest 25% after one year then monthly over 36 months; RSUs vest 25% after the first anniversary on the next quarterly date, then quarterly over three years.
Laura A. Williams, Chief Patient Officer of Ardelyx, Inc. (ARDX), reported multiple transactions on 08/26/2025 executed pursuant to a written plan under Rule 10b5-1. The filing shows an acquisition of 50,000 shares of common stock at $0.99 and two dispositions totaling 80,000 shares sold at a weighted average price of $6.121 (trades ranged $6.04–$6.20). Following these transactions, Ms. Williams beneficially owned 366,322 shares of common stock. The Form 4 also discloses a stock option with a $0.99 exercise price covering 50,000 shares that vests in 48 equal monthly installments beginning January 6, 2022, and expires January 6, 2032. The form is signed by an attorney-in-fact for Ms. Williams.
Mike Kelliher, Chief Business Officer and Director of Ardelyx, Inc. (ARDX), reported a sale of common stock on 08/21/2025. An automatic sell-to-cover executed upon the vesting of restricted stock units resulted in the disposition of 5,417 shares at $5.9317 per share to satisfy tax withholding. After the transaction, Kelliher beneficially owned 276,741 shares, reported as direct ownership. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/28/2025.
Ardelyx, Inc. (ARDX) filed a Form 144 notifying the proposed sale of 80,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $484,800.00 and an approximate sale date of 08/26/2025 on NASDAQ. The filing shows the securities were acquired partly by exercise of stock options on 08/26/2025 (50,000 shares, paid in cash) and partly as restricted stock units on 02/19/2024 (30,000 shares). The filer also reported a prior sale of 6,261 shares on 08/21/2025 generating gross proceeds of $37,138.37. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 notice language.
Laura A. Williams, listed as Chief Patient Officer and a director of Ardelyx, Inc. (ARDX), reported a non-derivative sale on 08/21/2025. The filing shows 6,261 shares of common stock were sold at $5.9317 per share under code S(1). The sale was executed pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units to cover withholding taxes. After the transaction, Williams is reported to beneficially own 396,322 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Ardelyx, Inc. insider Justin A. Renz, the company's Chief Financial Officer, reported a sale of 7,037 shares of ARDX common stock on 08/21/2025 at an average price of $5.9317 per share. After the transaction, Mr. Renz beneficially owned 409,052 shares. The filing states the sale was an automatic "sell-to-cover" triggered when restricted stock units vested, executed solely to satisfy withholding tax obligations. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Michael G. Raab, President & CEO and Director of Ardelyx, Inc. (ARDX), reported a sale of 45,687 shares of common stock on 08/21/2025 at a price of $5.9317 per share. The filing states the sale was an automatic sell-to-cover to satisfy tax withholding upon vesting of restricted stock units. After the transaction, Mr. Raab beneficially owns 1,502,250 shares directly, plus 24,364 shares held in his living trust and 1,000 shares held in trusts for his children. No derivative transactions are reported in this Form 4. The form is signed by an attorney-in-fact and dated 08/25/2025.
Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelyx, Inc. (ARDX), reported the disposition of 5,841 shares of the issuer's common stock on 08/21/2025. The sale was executed at $5.9317 per share under code S(1) and is described as an automatic sell-to-cover tied to the vesting of restricted stock units to satisfy withholding taxes. Following the transaction, Ms. Grammer beneficially owned 305,890 shares, held directly. The form is signed by the reporting person on 08/25/2025.
Eric Duane Foster, Chief Commercial Officer of Ardelyx, Inc. (ARDX), reported a routine stock transaction dated 08/21/2025. Pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units, 15,308 shares of Common Stock were sold at an average price of $5.9317 per share to satisfy applicable tax withholding. After the sale, Mr. Foster beneficially owned 301,498 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Foster on 08/25/2025. No derivatives or other transactions are reported.
Ardelyx, Inc. is reported to have a significant institutional stake held by Janus Henderson Group plc. The filing shows Janus Henderson beneficially owns 15,057,940 shares, representing 6.3% of the outstanding common stock, with shared voting and shared dispositive power over 15,057,940 shares. A related subsidiary, JHIUS, is disclosed as potentially beneficial owner of 14,928,999 shares (6.2%) and, together with JHIUKL and JHIAIFML, is identified as an indirect subsidiary that serves as a registered investment adviser to Managed Portfolios. The filer certifies these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
